A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
City of Hope Medical Center
City of Hope Medical Center
Toray Industries, Inc
Eli Lilly and Company
Emory University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Northwell Health
Ruhr University of Bochum
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
AstraZeneca
Canadian Cancer Trials Group
Critical Outcome Technologies Inc.
OHSU Knight Cancer Institute
University of Arizona
GOG Foundation
City of Hope Medical Center
University of Utah
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center